



FLUID OVERLOAD IN POST SURGICAL PATIENTS

A STEP TOWARDS PREDICTABLE AND PRECISE FLUID REMOVAL

Physicians face the daily challenge of managing fluid in post-op CV surgical patients. The Aquadex SmartFlow™ System allows for predictable and precise fluid removal with no clinically significant changes to electrolytes.

READMISSION

Nearly **1 of 5** patients who undergo cardiac operations require readmission¹

Fluid overload is among the **top 3** most common causes for first readmission within 30 days and beyond 30 days¹

POSTOPERATIVE COMPLICATIONS

Major postoperative complications are associated with significantly **worse survival** and **longer LOS**^{1,2,3}

Fluid overload has a significant association with the combined events of death, infection, bleeding, arrhythmia, and pulmonary edema⁴

A CLINICALLY PROVEN THERAPY FOR TREATING FLUID OVERLOAD

AQUADEX SMARTFLOW SYSTEM



BENEFITS OF ULTRAFILTRATION IN CARDIAC SURGERY PATIENTS

- Modified ultrafiltration reduces duration of assisted ventilation post-op cardiac surgery^{1,2,3}
- Ultrafiltration improves cardiac performance^{1,4,5,6}
- Ultrafiltration following cardiac surgery may reduce the need for blood transfusions^{4,7,8,9}
- Combined conventional and modified ultrafiltration is safe and effective in adult cardiac surgery patients^{1,3,4}

BENEFITS OF AQUADEX SMARTFLOW SYSTEM

- Simplified form of ultrafiltration that can be prescribed by ANY physician trained in extracorporeal therapy
- Easy setup and monitoring allowing 4:1 patient to nurse ratio
- Approximately 35 mL of extracorporeal blood volume in patented blood circuit
- No significant change to electrolyte balance

RX ONLY

INDICATION: The Aquadex SmartFlow System is indicated for: Continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

Aquadex SmartFlow™ is a trademark of CHF Solutions, Inc.

chf solutions

CUSTOMER SUPPORT

1-855-786-2778

Support@CHF-Solutions.com

www.chf-solutions.com

Sources: ^[1]Iribarne, A et al. Ann Thorac Surg. 2014;98:1274-80. ^[2]Crawford, T et al. Ann Thorac Surg. 2017;103:32-40. ^[3]Mariscalco, G et al. Ann Thorac Surg. 2011;92:1539-47. ^[4]Stein, A et al. Critical Care. 2012;16:R99. ^[5]Luciani GB, et al. Circulation. 2001 Sep 18;104(12 Suppl 1):1253-1259. ^[6]Kiziltepe U, et al. Ann Thorac Surg. 2001 Feb;71(2):684-93. ^[7]Grunenfelder et al. Eur J of Cardio Thoracic Surgery. 2000;17:77-83. ^[8]Sahoo TK, et al. Indian J Thorac Cardiovasc Surg. 2007 Jun;23(2):116-124. ^[9]Boga et al. Perfusion. 2000;15:143-150. ^[10]Onoe et al. Perfusion. 2001;16:37-42. ^[11]Boodhwani M et al. Eur J Cardiothorac Surg. ^[12]Torina et al. J of Thorac Cardiovasc Surg. 2012;144:663-70. ^[13]Papadopoulos et al. Perfusion. 2013;28:306-14.